X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (120) 120
oncology (72) 72
hematology (60) 60
female (45) 45
index medicus (43) 43
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (42) 42
male (41) 41
middle aged (41) 41
chronic myeloid-leukemia (34) 34
chronic myelogenous leukemia (33) 33
imatinib mesylate (32) 32
aged (29) 29
adult (27) 27
benzamides (27) 27
leukemia, myelogenous, chronic, bcr-abl positive - genetics (27) 27
animals (25) 25
fusion proteins, bcr-abl - genetics (24) 24
chronic myeloid leukemia (22) 22
antineoplastic agents - therapeutic use (21) 21
imatinib (21) 21
leukemia (20) 20
mice (19) 19
cancer (18) 18
medicine & public health (17) 17
pyrimidines - therapeutic use (17) 17
fusion proteins, bcr-abl - metabolism (16) 16
piperazines - therapeutic use (16) 16
phosphorylation (15) 15
signal transduction (14) 14
cell line, tumor (13) 13
dasatinib (13) 13
leukemia, myelogenous, chronic, bcr-abl positive - pathology (13) 13
pyrimidines - administration & dosage (13) 13
pyrimidines - pharmacology (13) 13
treatment outcome (13) 13
antineoplastic agents - pharmacology (12) 12
apoptosis (12) 12
protein kinase inhibitors - therapeutic use (12) 12
protein-tyrosine kinases - antagonists & inhibitors (12) 12
activation (11) 11
aged, 80 and over (11) 11
cell line (11) 11
hemic and lymphatic diseases (11) 11
human necessities (11) 11
hygiene (11) 11
k562 cells (11) 11
medical or veterinary science (11) 11
mutation (11) 11
piperazines - administration & dosage (11) 11
preparations for medical, dental, or toilet purposes (11) 11
acute lymphoblastic-leukemia (10) 10
adolescent (10) 10
bcr-abl (10) 10
biochemistry & molecular biology (10) 10
cml (10) 10
drug resistance, neoplasm (10) 10
genetics & heredity (10) 10
mice, nude (10) 10
philadelphia chromosome (10) 10
piperazines - pharmacology (10) 10
research (10) 10
transfection (10) 10
tyrosine (10) 10
care and treatment (9) 9
chemistry (9) 9
fusion proteins, bcr-abl - antagonists & inhibitors (9) 9
karyotyping (9) 9
leukemia, myelogenous, chronic, bcr-abl positive - metabolism (9) 9
protein kinase inhibitors - pharmacology (9) 9
remission induction (9) 9
time factors (9) 9
tumor cells, cultured (9) 9
apoptosis - drug effects (8) 8
kinases (8) 8
metallurgy (8) 8
specific therapeutic activity of chemical compounds ormedicinal preparations (8) 8
antineoplastic agents - administration & dosage (7) 7
genetic aspects (7) 7
heterocyclic compounds (7) 7
medicine, research & experimental (7) 7
myelodysplastic syndromes - genetics (7) 7
myelofibrosis (7) 7
oncology, experimental (7) 7
organic chemistry (7) 7
philadelphia-chromosome (7) 7
protein-tyrosine kinases - metabolism (7) 7
stem-cells (7) 7
survival (7) 7
therapy (7) 7
analysis (6) 6
antineoplastic combined chemotherapy protocols - therapeutic use (6) 6
blast crisis (6) 6
cell proliferation - drug effects (6) 6
chronic-phase (6) 6
gene (6) 6
gene expression (6) 6
growth (6) 6
myelodysplastic syndrome (6) 6
neoplasms (6) 6
precursor cell lymphoblastic leukemia-lymphoma - genetics (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


[Rinsho ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 2018, Volume 59, Issue 10, p. 2089
Fatal events during treatment with ABL tyrosine kinase inhibitors (ABL TKIs) have been reported, and there have been concerns of high mortality rate in... 
DNA Mutational Analysis | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Protein Kinase Inhibitors - toxicity | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - mortality
Journal Article
Arthritis Research & Therapy, ISSN 1478-6354, 2012, Volume 14, Issue Suppl 1, pp. O43 - O43
Journal Article
[Rinshō ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 10/2013, Volume 54, Issue 10, pp. 1682 - 1686
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 4249 - 4249
Abstract Introduction: Although ABL tyrosine kinase inhibitor (TKI), imatinib, nilotinib and dasatinib have demonstrated the potency against chronic myeloid... 
Journal Article
Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5155 - 5155
Abstract Introduction: Multiple myeloma (MM) is one of the hematological malignancy that affects the plasma cells in bone marrow. The treatment of MM patients... 
Journal Article
[Rinshō ketsueki] The Japanese journal of clinical hematology, ISSN 0485-1439, 06/2013, Volume 54, Issue 6, pp. 559 - 567
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 3150 - 3150
Abstract Background: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders characterized by no efficient hematopoiesis and frequent progression to... 
Journal Article
Blood, ISSN 0006-4971, 12/2016, Volume 128, Issue 22, pp. 5428 - 5428
Abstract Introduction: Chronic myeloid leukemia (CML) is characterized by the t(9:22) translocation known as the Philadelphia chromosome (Ph). Although ABL... 
Journal Article
Cancer Science, ISSN 1347-9032, 05/2009, Volume 100, Issue 5, pp. 970 - 977
Journal Article
Oncotarget, ISSN 1949-2553, 08/2018, Volume 9, Issue 65, pp. 32496 - 32506
Abelson murine leukemia viral oncogene homolog (ABL) tyrosine kinase inhibitors (TKIs) have been shown to be effective for treatment of chronic myeloid... 
T315I mutation | Aurora kinase | Chronic myeloid leukemia | ABL tyrosine kinase inhibitor | Cell cycle
Journal Article
International Journal of Hematology, ISSN 0925-5710, 9/2017, Volume 106, Issue 3, pp. 385 - 397
Journal Article
Experimental Hematology, ISSN 0301-472X, 09/2017, Volume 53, pp. S73 - S73
Journal Article
International Journal of Hematology, ISSN 0925-5710, 5/2006, Volume 83, Issue 4, pp. 294 - 300
Imatinib was developed as the first molecularly targeted therapy to specifically inhibit the BCR-ABL kinase in Philadelphia chromosome (Ph)-positive chronic... 
Resistance | Medicine & Public Health | Hematology | Tyrosine kinase inhibitor | SRC | BCR-ABL | Oncology | CHRONIC MYELOGENOUS LEUKEMIA | CHRONIC-PHASE | BLAST CRISIS | AMINOPYRIMIDINE INHIBITOR | resistance | CHRONIC MYELOID-LEUKEMIA | IMATINIB-RESISTANT | PH PLUS | PHILADELPHIA-CHROMOSOME | ACUTE LYMPHOBLASTIC-LEUKEMIA | tyrosine kinase inhibitor | HEMATOLOGY | IN-VITRO ACTIVITY | Protein Binding - genetics | Protein-Tyrosine Kinases - metabolism | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - chemistry | Protein-Tyrosine Kinases - genetics | Fusion Proteins, bcr-abl | Protein Binding - drug effects | Drug Design | Philadelphia Chromosome | Binding Sites - drug effects | Allosteric Regulation - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - enzymology | Allosteric Regulation - genetics | Gene Expression Regulation, Leukemic - drug effects | Binding Sites - genetics | Antineoplastic Agents - chemistry | Gene Amplification - drug effects | Drug Resistance, Neoplasm - genetics | Protein Kinase Inhibitors - therapeutic use | Mutation | Drug Resistance, Neoplasm - drug effects | Protein Structure, Tertiary - drug effects | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Phenols | Gene mutations | Leukemia
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 2769 - 2769
Abstract Introduction: The BCR-ABL1 fusion gene is a causative oncogene in chronic myeloid leukemia (CML) and 30-50% of acute lymphoblastic leukemia cases.... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 3693 - 3693
Abstract Introduction: Chronic myeloid leukemia (CML) is characterized by the t(9:22) translocation known as the Philadelphia chromosome (Ph). ABL tyrosine... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.